Health Trials

Metastatic Non-small Cell Lung Cancer (NSCLC)

3

Review clinical trials related to Metastatic Non-small Cell Lung Cancer (NSCLC). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Participants needed: 160
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Bristol-Myers SquibbUpdated: Jul 2, 2026Locations: 71
Eligibility criteria

Participants must have histologically confirmed diagnosis of stage IV non-small... [+4]

Participants must not have any documented actionable genomic alterations (AGAs)... [+3]

Read more
Status: Recruiting

Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously treated with immune checkpoint blockade (ICB). The hypotheses of this study are that a combination of ICB, cyclophosphamide, and bevacizumab prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.

Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: EuroCityClinic LLCUpdated: Aug 19, 2025Locations: 1
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 [+8]

Presence of clinically significant cardiovascular disease: severe or unstable is... [+15]

Read more
Status: Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany

Participants needed: 12,400
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: AIO-Studien-gGmbHUpdated: Feb 18, 2025Locations: 1Duration: 3 Years
Eligibility criteria

Age ≥ 18 years [+12]

Read more